Recent

% | $
Quotes you view appear here for quick access.

CEL-SCI Corporation Message Board

momentum2play 7 posts  |  Last Activity: Jul 12, 2016 9:55 AM Member since: Aug 24, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    CYTR implodes

    by nwboinvestor Jul 11, 2016 5:09 PM
    momentum2play momentum2play Jul 12, 2016 9:55 AM Flag

    He was and if you listen to Pyrr you will lose your investment. So far his picks is as good as AF!

    Sentiment: Strong Buy

  • UCLA researchers have developed a new combination immunotherapy to treat advanced brain cancer.

    The combination treatment works by preventing brain cancer cells from shielding themselves from a patient’s own immune responses.

    The three-year study, published Thursday, found that antibody blocking of an immune cell’s PD-1 surface receptors combined with a dendritic cell vaccine is more effective than using either one alone. Previous studies have shown these surface receptors to suppress normal immune response while dendritic cell vaccinations induce normal immune response, through intracranial immune cell activation.

    Robert M. Prins, leader of the cancer research and member of the UCLA Jonsson Comprehensive Cancer Center, said he and his team discovered that effective immunity to glioblastoma requires a robust killer T cell response in order to attenuate immune cells within the tumor.

    Although PD-1 antibody blockade removes the shield that glioblastomas activate to hide from a patient’s immune system, it may not be successful by itself in tumors that do not have sufficient infiltration of killer T cells, a type of white blood cell that lyses cancer cells. The dendritic cell vaccination allows necessary infiltration of these killer T cells into the tumors. Thus, the two combined treatment of both vaccine and antibody blockade allow for a more effective immunotherapy.

    Glioblastoma constitutes about 15.4 percent of all primary brain tumors, according to the American Brain Tumor Association. Most people who are diagnosed face a median survival rate of 14.6 months.

    The research findings are the first to outline how an effective immune response can be activated in the advanced brain cancer, said Prins.

    Prins and Linda Liau, another leader of the research team, have filed to obtain a patent on the glioblastoma vaccine combination treatment.

    UCLA researchers have developed a new combination immunotherapy to treat advanced brain cancer.

    Sentiment: Strong Buy

  • momentum2play momentum2play Jul 11, 2016 12:27 PM Flag

    I also added another 4.5 thousand shares to my portfolio for the same reason. When I read the article on Juno. I thought another one bits the dust on really serious reasons. It will take them a while to start it up again at least 6 months. DCVAX has such a great safety record and at these prices time to stock up. I plan on more buys on a weekly basis.

    Sentiment: Buy

  • Reply to

    Here is link to article on DCVAX. Very detailed

    by armalitem15 Jul 8, 2016 11:13 AM
    momentum2play momentum2play Jul 9, 2016 9:39 AM Flag

    Here is a more detailed version of what it does cover!
    freepatentsonline.com/20150273033.pdf

    Sentiment: Strong Buy

  • Reply to

    Here is link to article on DCVAX. Very detailed

    by armalitem15 Jul 8, 2016 11:13 AM
    momentum2play momentum2play Jul 8, 2016 3:21 PM Flag

    A patent they are all mentioned there on Pdl1 blocker.

    Sentiment: Strong Buy

  • Reply to

    Here is link to article on DCVAX. Very detailed

    by armalitem15 Jul 8, 2016 11:13 AM
    momentum2play momentum2play Jul 8, 2016 3:19 PM Flag

    What is this :

    United States Patent Application 20150202291
    Kind Code A1
    Bosch; Marnix Leo ; et al. July 23, 2015
    COMBINATIONS OF CHECKPOINT INHIBITORS AND THERAPEUTICS TO TREAT CANCER

    Abstract
    A combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, the efficacy of anti-tumor immune responses or a medically beneficial response by a tumor.
    Inventors: Bosch; Marnix Leo; (Clyde Hill, WA) ; Ganjel; James Kelly; (Bethesda, MD) ; Powers; Linda F.; (Bethesda, MD) ; Liau; Linda M.; (Los Angeles, CA) ; Prins; Robert M.; (Pacific Palisades, CA)
    Applicant:
    Name City State Country Type

    COGNATE BIOSERVICES, INC.
    NORTHWEST BIOTHERAPEUTICS
    The Regents of the University of California
    RevImmune, Inc.
    Hanover
    Bethesda
    Oakland
    Hanover
    MD
    MD
    CA
    MD
    US
    US
    US
    US
    Family ID: 1000001099221
    Appl. No.: 14/534158
    Filed: November 5, 2014
    Related U.S. Patent Documents
    Application Number Filing Date Patent Number
    61900309 Nov 5, 2013
    61900355 Nov 5, 2013

    Sentiment: Strong Buy

  • momentum2play by momentum2play Jun 30, 2016 9:53 AM Flag

    Berlin, Germany:
    Quote:
    TARGETING SOLID TUMOURS: HOW TO ENABLE THE NEXT GREAT STEP IN CELLULAR CANCER IMMUNOTHERAPY?

    September 22, 2016
    16:25 - 16:30
    CHAIR'S INTRODUCTION
    Linda Powers
    LINDA POWERS
    CEO
    Northwest Biotherapeutics

    And don't forget, she speaks in London one Day before that.

    London England
    September 21, 2016

    Flipper65833

    Sentiment: Strong Buy

CVM
0.27-0.0024(-0.88%)Sep 28 4:02 PMEDT